Approvals/HSA/THIOTEPA RIEMSER POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15MG/VIAL

Approved

THERAPEUTIC

THIOTEPA RIEMSER POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15MG/VIAL

Thymoorgan Pharmazie GmbH (GERMANY)🇸🇬 Health Sciences Authority

Approval Date: Jun 20, 2024
Approval ID: cd027ec6e5926e03
Company: Thymoorgan Pharmazie GmbH (GERMANY)
Type: Therapeutic

Approval Details

Approval Id: cd027ec6e5926e03
Drug Name: THIOTEPA RIEMSER POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15MG/VIAL
Product Name: THIOTEPA RIEMSER POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15MG/VIAL
Approval Number: SIN17027P
Approval Date: 2024-06-20
Registrant: NYPRAX PHARMA PTE. LTD.
Licence Holder: NYPRAX PHARMA PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Dosage: 4.2 Posology and method of administration Thiotepa Riemser administration must be supervised by a physician experienced in conditioning treatment prior to haematopoietic progenitor cell transplantation. Posology Thiotepa Riemser is administered at different doses, in combination with other chemotherapeutic medicinal products, in patients with haematological diseases or solid tumours prior to HPCT. Thiotepa Riemser posology is reported, in adult and paediatric patients, according to the type of HPCT (autologous or allogeneic) and disease. Adults AUTOLOGOUS HPCT Haematological diseases The recommended dose in haematological diseases ranges from 125 mg/m2/day (3.38 mg/kg/day) to 300 mg/m2/day (8.10 mg/kg/day) as a single daily infusion, administered from 2 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 900 mg/m2 (24.32 mg/kg), during the time of the entire conditioning treatment. LYMPHOMA The recommended dose ranges from 125 mg/m2/day (3.38 mg/kg/day) to 300 mg/m2/day (8.10 mg/kg/day) as a single daily infusion, administered from 2 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 900 mg/m2 (24.32 mg/kg), during the time of the entire conditioning treatment. CENTRAL NERVOUS SYSTEM (CNS) LYMPHOMA The recommended dose is 185 mg/m2/day (5 mg/kg/day) as a single daily infusion, administered for 2 consecutive days before autologous HPCT, without exceeding the total maximum cumulative dose of 370 mg/m2 (10 mg/kg), during the time of the entire conditioning treatment. Breast Cancer The recommended dose ranges from 120 mg/m2/day (3.24 mg/kg/day) to 250 mg/m2/day (6.76 mg/kg/day) as a single daily infusion, administered from 3 up to 5 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 800 mg/m2 (21.62 mg/kg), during the time of the entire conditioning treatment. ALLOGENEIC HPCT Haematological diseases The recommended dose in haematological diseases ranges from 185 mg/m2/day (5 mg/kg/day) to 481 mg/m2/day (13 mg/kg/day) divided in one or two daily infusions, administered from 1 up to 3 consecutive days before allogeneic HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 555 mg/m2 (15 mg/kg), during the time of the entire conditioning treatment. LYMPHOMA The recommended dose in lymphoma is 370 mg/m2/day (10 mg/kg/day) divided in two daily infusions before allogeneic HPCT, without exceeding the total maximum cumulative dose of 370 mg/m2 (10 mg/kg), during the time of the entire conditioning treatment. LEUKAEMIA The recommended dose ranges from 185 mg/m2/day (5 mg/kg/day) to 481 mg/m2/day (13 mg/kg/day) divided in one or two daily infusions, administered from 1 up to 2 consecutive days before allogeneic HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 555 mg/m2 (15 mg/kg), during the time of the entire conditioning treatment. Paediatric population AUTOLOGOUS HPCT CNS TUMOURS The recommended dose ranges from 250 mg/m2/day (10 mg/kg/day) to 350 mg/m2/day (14 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 1 050 mg/m2 (42 mg/kg), during the time of the entire conditioning treatment. ALLOGENEIC HPCT Haematological diseases The recommended dose in haematological diseases ranges from 125 mg/m2/day (5 mg/kg/day) to 250 mg/m2/day (10 mg/kg/day) divided in one or two daily infusions, administered from 1 up to 3 consecutive days before allogeneic HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 375 mg/m2 (15 mg/kg), during the time of the entire conditioning treatment. LEUKAEMIA The recommended dose is 250 mg/m2/day (10 mg/kg/day) divided in two daily infusions, administered before allogeneic HPCT, without exceeding the total maximum cumulative dose of 250 mg/m2 (10 mg/kg), during the time of the entire conditioning treatment. THALASSEMIA The recommended dose ranges from 200 mg/m2/day (8 mg/kg/day) to 250 mg/m2/day (10 mg/kg/day) divided in two daily infusions, administered before allogeneic HPCT without exceeding the total maximum cumulative dose of 250 mg/m2 (10 mg/kg), during the time of the entire conditioning treatment. REFRACTORY CYTOPENIA The recommended dose is 125 mg/m2/day (5 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before allogeneic HPCT, without exceeding the total maximum cumulative dose of 375 mg/m2 (15 mg/kg), during the time of the entire conditioning treatment. GENETIC DISEASES The recommended dose is 125 mg/m2/day (5 mg/kg/day) as a single daily infusion, administered for 2 consecutive days before allogeneic HPCT, without exceeding the total maximum cumulative dose of 250 mg/m2 (10 mg/kg), during the time of the entire conditioning treatment. SICKLE CELL ANAEMIA The recommended dose is 250 mg/m2/day (10 mg/kg/day) divided in two daily infusions, administered before allogeneic HPCT, without exceeding the total maximum cumulative dose of 250 mg/m2 (10 mg/kg), during the time of the entire conditioning treatment. Special populations Renal impairment Studies in renally impaired patients have not been conducted. As thiotepa and its metabolites are poorly excreted in the urine, dose modification is not recommended in patients with mild or moderate renal insufficiency. However, caution is recommended (see sections 4.4 and 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Hepatic impairment Thiotepa has not been studied in patients with hepatic impairment. Since thiotepa is mainly metabolised through the liver, caution needs to be exercised when thiotepa is used in patients with pre-existing impairment of liver function, especially in those with severe hepatic impairment. Dose modification is not recommended for transient alterations of hepatic parameters (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Elderly The administration of thiotepa has not been specifically investigated in elderly patients. However, in clinical studies, a proportion of patients over the age of 65 received the same cumulative dose as the other patients. No dose adjustment was deemed necessary. Method of administration Thiotepa Riemser is for intravenous use. It must be administered by a qualified healthcare professional as a 2 – 4 hours intravenous infusion via a central venous catheter. Each vial of 15 mg thiotepa must be reconstituted with 1.5 mL of sterile water for injections. Each vial of 100 mg thiotepa must be reconstituted with 10 mL of sterile water for injections. The total volume of reconstituted vials to be administered should be further diluted in 500 mL of sodium chloride 9 mg/mL (0.9%) solution for injection prior to administration (1 000 mL if the dose is higher than 500 mg). In paediatric patients, if the dose is lower than 250 mg, an appropriate volume of sodium chloride 9 mg/mL (0.9%) solution for injection may be used in order to obtain a final Thiotepa Riemser concentration between 0.5 and 1 mg/mL. For instructions on reconstitution and further dilution prior to administration, see section 6.6– please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information. Precautions to be taken before handling or administering the medicinal product Topical reactions associated with accidental exposure to thiotepa may occur. Therefore, the use of gloves is recommended in preparing the solution for infusion. If thiotepa solution accidentally contacts the skin, the skin must be immediately thoroughly washed with soap and water. If thiotepa accidentally contacts mucous membranes, they must be flushed thoroughly with water (see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Route Of Administration: INTRAVENOUS
Indication Info: 4.1 Therapeutic indications Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products: <ul> <li>with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;</li> <li>when high dose chemotherapy with HPCT support is appropriate for the treatment of breast cancer in adult patients and CNS tumours in paediatric patients.</li> </ul>
Contraindications: 4.3 Contraindications Hypersensitivity to the active substance. Pregnancy and lactation (see section 4.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Concomitant use with yellow fever vaccine and with live virus and bacterial vaccines (see section 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Atc Code: L01AC01
Pharma Manufacturer Name: NYPRAX PHARMA PTE. LTD.
Company Detail Path: /organization/nyprax-pharma-pte-ltd

Active Ingredients

Thiotepa

15.0 mg/vial

Thiotepa

15.0 mg/vial

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Jun 20, 2024

Approval ID

cd027ec6e5926e03

Type

Therapeutic

Back to HSA Approvals